ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourBadreddin Edris, Matt van de Rijn, Cheng‐Han Lee et al.|The Journal of Pathology|2012Cited by 77
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Matt van de Rijn, Stephen B. Willingham et al.|Proceedings of the National Academy of Sciences|2013Cited by 55
Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal TumorThomas Mühlenberg, Sebastian Bauer|PLoS ONE|2015Cited by 23